Evidence map›Paper›PMID 26677441›Full record

ReviewWorld journal of clinical oncology2015

Cervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choices.

Rosa Catarino, Patrick Petignat, Gabriel Dongui, Pierre Vassilakos

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
137citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

137 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Article
  13. Article
  14. Article
  15. HPV Self-Sampling for Cervical Cancer Screening in Morocco: A Cross-Sectional Study.Asian Pacific journal of cancer prevention : APJCP · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

77 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rosa CatarinoRosa Catarino, Patrick Petignat, Division of Gynaecology, Department of Gynaecology and Obstetrics, Geneva University Hospitals, 1205 Geneva, Switzerland.
Patrick PetignatRosa Catarino, Patrick Petignat, Division of Gynaecology, Department of Gynaecology and Obstetrics, Geneva University Hospitals, 1205 Geneva, Switzerland.
Gabriel DonguiRosa Catarino, Patrick Petignat, Division of Gynaecology, Department of Gynaecology and Obstetrics, Geneva University Hospitals, 1205 Geneva, Switzerland.
Pierre VassilakosRosa Catarino, Patrick Petignat, Division of Gynaecology, Department of Gynaecology and Obstetrics, Geneva University Hospitals, 1205 Geneva, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer (CC) represents the fourth most common malignancy affecting women all over the world and is the second most common in developing areas. In these areas, the burden from disease remains important because of the difficulty in implementing cytology-based screening programmes. The main obstacles inherent to these countries are poverty and a lack of healthcare infrastructures and trained practitioners. With the availability of new technologies, researchers have attempted to find new strategies that are adapted to low- and middle-income countries (LMIC) to promote early diagnosis of cervical pathology. Current evidence suggests that human papillomavirus (HPV) testing is more effective than cytology for CC screening. Therefore, highly sensitive tests have now been developed for primary screening. Rapid molecular methods for detecting HPV DNA have only recently been commercially available. This constitutes a milestone in CC screening in low-resource settings because it may help overcome the great majority of obstacles inherent to previous screening programmes. Despite several advantages, HPV-based screening has a low positive predictive value for CC, so that HPV-positive women need to be triaged with further testing to determine optimal management. Visual inspection tests, cytology and novel biomarkers are some options. In this review, we provide an overview of current and emerging screening approaches for CC. In particular, we discuss the challenge of implementing an efficient cervical screening adapted to LMIC and the opportunity to introduce primary HPV-based screening with the availability of point-of-care (POC) HPV testing. The most adapted screening strategy to LMIC is still a work in progress, but we have reasons to believe that POC HPV testing makes part of the future strategies in association with a triage test that still needs to be defined.

Indexed as

Cervical cancer screeningHuman papillomavirus testingLow- and middle-income countries

Identifiers

PMID26677441
PMCPMC4675913

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.